

Barriers and Facilitators to Community Pharmacist-Provided Injectable Naltrexone for Formerly Incarcerated Individuals During Community Reentry in Wisconsin

Authors:

Jason S. Chladek, PhD, PharmD, MPH^{1,2}

Michelle A. Chui, PharmD, PhD^{2,3}

¹Grossman School of Medicine, New York University, 180 Madison Ave, New York, NY, 10016

²Division of Social and Administrative Sciences, University of Wisconsin-Madison School of Pharmacy, 777 Highland Ave, Madison, WI, 53705

³Sonderegger Research Center, University of Wisconsin-Madison School of Pharmacy, 777 Highland Ave, Madison, WI, 53705

Corresponding author:

Jason S. Chladek, PhD, PharmD, MPH

180 Madison Ave

New York, NY 10016

jason.chladek@nyulangone.org

715-304-6647

Authors contributions:

JC was responsible for conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, writing the original draft, and reviewing and editing. MC was responsible for conceptualization, supervision, and reviewing and editing. Both authors read and approved the final manuscript.

Acknowledgements:

The authors would like to thank James H. Ford II and Olayinka O. Shiyanbola for their contributions in conceptualizing this manuscript.

Funding:

This work was funded by grants TL1TR002375 and UL1TR002373 awarded to the University of Wisconsin-Madison Institute for Clinical and Translational Research (ICTR) through the National Center for Advancing Translational Sciences (NCATS).

Declaration of interest statement:

The authors have nothing to declare.

Abstract

Medications for opioid use disorder (MOUD), including injectable naltrexone, are a key component in the treatment of opioid use disorder (OUD). These medications are especially important for individuals transitioning out of correctional facilities and back into their communities, as individuals receiving MOUD are 85% less likely to die due to drug overdose in the first month post-release and have a 32% lower risk of rearrest. Unfortunately, few formerly incarcerated individuals have access to MOUD upon reentry, incurring a 40-fold greater likelihood of overdose following release compared to the general population. While 84% of Wisconsin jails offering MOUD offer naltrexone, less than half provide linkage to community treatment for reentering individuals. In Wisconsin, community pharmacists have the authority to provide naltrexone injections. However, they have not been explored as a resource for improving access to this medication for formerly incarcerated individuals. As a first step, the goal of this study was to understand the barriers and facilitators impacting access to community pharmacist-provided injectable naltrexone for this patient population during community reentry period. The researcher conducted semi-structured interviews with 18 individuals representing five stakeholder groups. Deductive and inductive content analysis were used to identify barrier and facilitator categories across the five levels of the Socioecological Model. Overall, participants discussed factors at every level, and many barriers and facilitators confirmed findings from existing literature focused on MOUD access for formerly incarcerated individuals. Participants also identified factors more specific to community pharmacies, including 1) lack of interagency collaboration between pharmacists, prescribers, and correctional facilities and 2) lack of awareness of community pharmacist-provided MOUD services. Future research should explore interventions to address the barriers identified in this study and improve connections between community pharmacists and formerly incarcerated individuals. This work can help ensure that these individuals are given the chance to successfully reintegrate into society.

Keywords

Community pharmacists, MOUD, injectable naltrexone, formerly incarcerated, OUD, reentry

Introduction

The opioid epidemic is a major public health issue in the United States. More than three million citizens suffer from opioid use disorder (OUD), a problematic pattern of opioid use leading to health problems and/or social distress.¹⁻³ Specifically, Wisconsin has been significantly impacted by this problem, with opioid overdose deaths increasing 900% from 1999 to 2019. In 2022 alone, there were 1,464 opioid-related deaths in the state.⁴⁻⁵

OUD is highly prevalent among individuals involved in the criminal justice system. In 2020, the Wisconsin Department of Corrections (DOC) reported 325 deaths among those admitted to probation and 276 among those released from prison.⁶ Medications for opioid use disorder (MOUD), which include methadone, buprenorphine, and naltrexone, are a key component in the treatment of OUD, and are especially important for individuals transitioning out of correctional facilities and back into their communities.⁷ Formerly incarcerated individuals receiving MOUD are 85% less likely to die due to drug overdose in the first month after release and have a 32% lower risk of rearrest.⁸

Unfortunately, few formerly incarcerated individuals are able to access sustainable MOUD treatment upon community reentry, missing a critical tool for rehabilitation and incurring a 40-fold greater likelihood of opioid overdose following release compared to the general population.⁹ Previous work has shown that in individuals who are released with doses of MOUD, less than half continue use in the community.¹⁰⁻¹² In Wisconsin, only 47.7% of jails provided those being released with a community link to MOUD.¹³⁻¹⁴ The Substance Abuse and Mental Health Services Administration (SAMHSA) reports that 40-50% of these individuals are rearrested within a year of release, and 75% relapse to opioid use within three months.¹⁵ Furthermore, lack of access to MOUD during reentry is tied to racial and ethnic disparities, as Black, Hispanic, and Latine populations are disproportionately impacted.¹⁶⁻¹⁷ Overall, there is a clear need to improve access to MOUD for formerly incarcerated individuals during community reentry. The volume of research in progress shows that more professionals are recognizing this need, but this work remains limited.¹⁸

While current research efforts are limited, there are certain components of existing interventions and programs that show promise. For example, the success of mobile treatment demonstrates that an accessible location for MOUD treatment can facilitate access. Another unexplored resource that could provide an accessible location is community pharmacies.¹⁹ Community pharmacists are not only considered more accessible than other healthcare providers, but 96.5% of the U.S. population lives within 10 miles of a community pharmacy.²⁰⁻²¹

Wisconsin community pharmacists have had the authority to administer long-acting injectable naltrexone treatments since 2019.²² For formerly incarcerated individuals, injectable naltrexone is associated with improved treatment retention, reduced healthcare utilization, reduced rates of reincarceration, reduced opioid relapse, and improved medication adherence. Additionally, injectable naltrexone is long-lasting and has a decreased risk of abuse potential, making it widely accepted and used among justice-impacted individuals.²³

Long-term, improving connections between formerly incarcerated individuals and community pharmacists can help increase access to MOUD during the community reentry period. As a first step, the goal of this study is to understand the exiting barriers and facilitators to this care. While previous work has examined barriers and facilitators to MOUD for formerly incarcerated

individuals, as well as barriers and facilitators faced by community pharmacists in providing these services, community pharmacist-provided injectable naltrexone has not been explored for this particular population.^{22,24-35} This study will utilize semi-structured interviews with various stakeholder groups to comprehensively identify existing barriers and facilitators impacting the availability, access, and use to these services for formerly incarcerated individuals.

Materials and Methods

Participants and sampling

Participants were recruited for individual semi-structured interviews between September 2023 and January 2024. Study participants were recruited if they were identified as potential stakeholders in transitions of care for formerly incarcerated individuals with opioid use disorder during the community reentry process. Individuals fell within one of five different stakeholder groups: 1) MOUD prescribers with experience providing care for formerly incarcerated patients, 2) community pharmacists with experience administering naltrexone injections for formerly incarcerated patients, 3) professionals working in a correctional setting with experience assisting formerly incarcerated individuals with OUD during reentry planning, 4) professionals working for a community organization or non-profit with experience assisting formerly incarcerated individuals with OUD during reentry planning, and 5) individual patients with a history of incarceration and using injectable naltrexone for OUD treatment OR a family member/caregiver of an individual with a history of incarceration and using injectable naltrexone for OUD treatment.

Participants from all five stakeholder groups were 18 years of age or older, able to speak and understand English, and residing in Wisconsin. The goal of recruiting individuals from different stakeholder groups was to comprehensively understand the barriers and facilitators to accessing community pharmacist-provided injectable naltrexone from multiple perspectives. This approach was also used to help ensure that barriers and facilitators from every level of the Socioecological Model were discussed. Individual patients and family members/caregivers were combined into one category, as it was anticipated that both groups would offer similar perspectives. Additionally, patients and family members/caregivers were not recruited from the same family.

The lead researcher had established relationships with several primary health clinics, pharmacies, and community organizations throughout Wisconsin, which were leveraged to identify and recruit participants. Initial recruitment was limited, especially concerning correctional staff and formerly incarcerated patients, so snowball sampling was utilized to identify additional participants who fit the inclusion criteria. In total, 18 participants were recruited, as shown in Table 1. This study was deemed exempt by the (XXXX) Institutional Review Board.

Procedures

All potential participants were informed of the study and invited to participate via email. After indicating an interest in participating, they were emailed an informational sheet about the project and interviews were scheduled. The informational sheet was reviewed by the researcher on the call prior to the start of the interview, after which verbal consent to participate was obtained. The lead researcher emphasized that there was no obligation to participate, and participation was voluntary and could be stopped at any time. All interviews were conducted via Zoom by the lead researcher. Interviews were audio recorded to help facilitate transcription and took 45 minutes to

1 hour. After the interview, participants were sent a five-minute demographic survey, which was returned to the researcher via email. Participants were compensated with \$60 gift cards after completion of the interview and survey.

The lead researcher conducted semi-structured interviews to identify the barriers and facilitators to community pharmacist-provided injectable naltrexone for formerly incarcerated individuals during community reentry. Two interview guides were created by the researcher that aligned with 1) providers, pharmacists, or staff and 2) patients, family members, or caregivers. The researcher anticipated that the use of community pharmacist-provided injectable naltrexone by formerly incarcerated individuals during reentry was limited, and not every participant would have direct experience with coordinating, providing, or receiving these services. As a result, the interview guides included questions for those with or without direct experience. Participants were first asked whether or not they had experience coordinating, providing, or receiving community pharmacist-provided naltrexone injections. If not, participants were asked to discuss anticipated barriers and facilitators based on their perceptions and/or previous experiences with reentry planning and using community pharmacies for healthcare services. Additionally, the researcher did not ask about any experiences related to drug abuse or addiction outside of access to treatment, and participants were told that they did not have to answer any questions or share any details they were uncomfortable discussing.

Data coding and analysis

The interviews were transcribed verbatim, de-identified, and verified for accuracy. All participants were assigned an ID number based on their stakeholder group. Transcripts were entered into NVivo, a qualitative data software package (released in March 2020).³⁶ The researchers performed deductive and inductive qualitative content analysis as outlined Elo & Kyngäs.³⁷ Both deductive and inductive approaches were used, as there is some previous knowledge on the barriers and facilitators that impact MOUD access for formerly incarcerated individuals, as well as factors impacting community pharmacists' abilities to implement injectable naltrexone services. However, knowledge related specifically to community pharmacist-provided injectable naltrexone for formerly incarcerated individuals is highly limited.

First, the lead researcher developed a categorization matrix based on the five domains of the Socioecological Model, visualized in Table 2. The Socioecological Model, as shown in Figure 1, is a multilevel model that conceptualizes factors impacting health behaviors and outcomes, as well as the interactions between these factors. It also supports the idea that behaviors both affect and are affected by various contexts.³⁸⁻⁴¹ The Model has been used extensively in public and population health efforts, including identifying barriers and facilitators to healthcare services. It has also been applied to studies focused on vulnerable populations, including individuals with a history of incarceration and/or substance use disorders.^{32,40,42-50}

The researchers applied a deductive approach by analyzing the transcripts line-by-line and coding the data according to the matrix. Factors were categorized as a barrier or facilitator depending on whether the participant was talking about availability, access, and/or use of community pharmacist-provided injectable naltrexone being hindered or supported by that specific factor. To determine the level of the Socioecological Model, the researchers evaluated the context of each factor. For example, if a participant stated that they did not have personal access to a car or mode of transportation, this would have been coded to the individual level. However, if a participant stated that their neighborhood did not have reliable public

transportation, this would have been coded to the community level. Any discrepancies were resolved during discussions between both coders.

Next, an inductive approach was used to group the data within each domain and create higher order categories. Development of categories was supported and confirmed through discussions between researchers. Any ambiguities were also addressed during these discussions. The lead researcher created a comparative analysis table to highlight which stakeholder groups discussed each of the categories (for both barriers and facilitators). This was used to compare responses between groups and highlight convergence and divergence across the different stakeholders. Finally, representative quotes were selected for each of the categories. Overall, this process was guided by the four-dimension criteria of qualitative research.⁵¹

Results

In total, 18 stakeholders participated in an interview. Participant demographics are outlined in Table 3. The Socioecological Model offered a framework for conceptualizing the factors impacting access to community pharmacist-provided naltrexone injections for formerly incarcerated individuals during the community reentry period.³⁸⁻⁴¹

For each level of the Socioecological Model, categories related to barriers and facilitators were distinguished, as displayed in Table 4. Table 5 and 6 show the comparative analysis for which stakeholder groups discussed each barrier or facilitator category, respectively. Overall, although participants belonged to different stakeholder groups and were speaking from different vantage points, many of their responses overlapped. As a result, the categories below pertain to the whole sample, and variations or nuances between stakeholder groups are discussed where applicable. Tables 7 and 8 highlight representative quotes for each of the categories, as well as the stakeholder group associated with the quote. All table colors correspond to the levels of the Socioecological Model as shown in Figure 1.

Public Policy Level

Overall, participants did not heavily discuss barriers and facilitators at the public policy level. Most of the discussion at this level centered around cost. For example, several participants said that the cost of naltrexone injections creates a major barrier. Few added that the cost of the medication greatly exceeds the reimbursement to the community pharmacies, so there is no financial incentive for them to provide the services or invest time in the infrastructure needed to provide injections. Overall, the expense can deter community pharmacists from providing the injections, limiting access to formerly incarcerated patients. Additionally, an MOUD prescriber added that the high cost of drug testing can create similar barriers, especially if community pharmacists take on the responsibility of testing patients prior to injections. Lastly, participants explained that patients face barriers because they are required to obtain a prescription from a provider for injectable naltrexone prior to visiting the community pharmacy. This can not only add additional steps for the patient, but potentially for the community pharmacists.

An organizational/non-profit staff member mentioned a potential facilitator at the public policy level. They discussed the classification of OUD as a disability under the American Disabilities Act (ADA), stating that this could facilitate treatment access for formerly incarcerated individuals. However, they did not offer additional information on how this would directly apply to community pharmacist-provided naltrexone injections compared to other treatment options.

Community Level

While discussing barriers to community pharmacist-provided naltrexone injections, many participants focused on stigma, both within the community and among providers. Stigma towards formerly incarcerated patients and treatments for substance use disorder, including OUD, can limit available services, as well as patients' desires to seek treatment. Most of the participants noted that a major barrier is a lack of interagency collaboration between MOUD prescriber clinics, community pharmacies, and correctional institutions. Specifically, these organizations do not communicate about the healthcare status or needs of individuals transitioning back into the community, nor collaborate to facilitate treatment. Not only are releases of information an obstacle, but professionals may be unclear or make assumptions about specific responsibilities. Additionally, several participants noted that there is simply a lack of available prescribers and injectors within the community, including community pharmacists who provide injections. This not only compounds the barrier of needing to obtain a prescription, but does not provide patients with the full opportunity to utilize community pharmacists for treatment.

In terms of facilitators, only one main factor was identified at this level. A majority of participants from all stakeholder groups shared that the accessible location of pharmacies within the community could support treatment for formerly incarcerated individuals. Participants noted that this could be especially true for those who don't have reliable transportation, as there is a good chance that there is a community pharmacy within a reasonable walking distance.

Organizational Level

At this level, discussions focused on the community pharmacy as the organization of interest. First, several participants shared that community pharmacists may face administrative constraints to providing naltrexone injections. Specifically, they mentioned that community pharmacists can be faced with additional paperwork, and they may lack the ability to properly document individuals receiving injections. Next, a few participants shared that community pharmacies do not advertise injectable naltrexone services. This is due to deliberate choices by management or because the pharmacies lack the capacity to market their services to large audiences. The participants also added that many community pharmacists do not have the ability to provide pre-injection services, such as drug testing, or other services related to OUD treatment, including counseling or therapy. Overall, this can add additional work for community pharmacists or deter formally incarcerated individuals from using community pharmacists for injections.

When discussing facilitators, many participants representing all stakeholder groups explained that community pharmacies can offer more flexibility with appointments. Patients either don't need to make an appointment or can easily and quickly make an appointment and often be seen the same day. Additionally, compared to other treatment options, patients have an easier time switching between community pharmacies if necessary. Also, participants added that community pharmacies can provide a nonjudgmental environment for formerly incarcerated individuals, making them comfortable enough to receive treatment at these sites. However, this category showed discordance, as a couple participants expressed concerns that they may feel judged, or the pharmacy wouldn't provide enough privacy. One said, "The local pharmacy, these people could be, like, judgmental about a person's addiction... So, I think the judgement could be an issue or feeling different when you walk in, you know?" (Patient/family member/caregiver). The other stated, "You're in a public place that anyone can get into. You sit down and could have anyone you know sitting next to you... which may be a little weird now that I'm thinking about

it,” (Patient/family member/caregiver). Lastly, a few participants mentioned that community pharmacies have more convenient hours than other treatment options, facilitating access for formerly incarcerated individuals. However, as with the previous facilitators, there was some disagreement among participants. In talking about pharmacy hours, a participant said, “And their hours are usually awful too. They’re not usually open. Community pharmacies at, like, [closed by] 6:30,” (Organizational staff). Another added, “So, like, with community pharmacies specifically, like, I know some of the barriers are, like, their hours. Like, they’re not usually open on Sundays, right? They have short Saturday hours. And so, for my patients that, like, again, are the off-shift workers, they can’t get their medicines from a community pharmacy,” (MOUD prescriber).

Interpersonal Level

One main category emerged regarding barriers at the interpersonal level. MOUD prescribers and patients/family members/caregivers explained that treatment access can be hindered if formerly incarcerated individuals are released into the same home or social environment they were in prior to incarceration. They added that this often exposes these individuals to “negative” influences or temptations, causing them to fall back into old patterns of opioid use.

Compared to barriers, more facilitators were identified at this level. First, the majority of participants stated that access to naltrexone injections could be supported by patient advocates. For example, these advocates could include family members, friends, peer support specialists, or case managers. Participants added that these advocates could help keep patients accountable to their treatment schedule and goals. This facilitator was identified by participants from all stakeholder groups. Second, several participants, also representing every stakeholder group, added that if individuals have a positive, trusting, and respectful relationship with their providers, including community pharmacists, treatment is facilitated. Finally, outside of relationships, community pharmacist participants said that treatment for formerly incarcerated patients is facilitated if the pharmacy utilizes reminders via call or text.

Individual Level

At the individual level, participants added that there is limited awareness that community pharmacists can and/or do provide naltrexone injections. Participants also noted that some patients are not only unaware that community pharmacists can provide these services, but that injectable naltrexone exists as a treatment option. Lack of awareness also prevents other non-pharmacist professionals from referring patients to community pharmacists or educating patients on this option. It also prevents reentry staff from recognizing this resource and connecting formerly incarcerated individuals to community pharmacist-provided treatment.

Additionally, the stakeholders identified several resources that create substantial barriers for formerly incarcerated individuals when not available. Nearly all participants discussed that a lack of reliable transportation – either private or public transportation – could inhibit access to naltrexone injections via community pharmacies. In addition to transportation, both a lack of insurance and lack of stable housing were identified several participants. In particular, a lack of reliable transportation was discussed by participants from all stakeholder groups.

Outside of these resources, non-patient participants described that formerly incarcerated individuals may have other responsibilities that take priority over finding and receiving

treatment. Examples include finding a job, meeting with probation or parole officers, or caring for other family members, including children. These responsibilities may not only be prioritized over treatment, but create barriers for patients from a time standpoint. A few participants added that the potential side effects experienced by individuals receiving naltrexone injections, including injection site pain, may deter them from wanting to use this option.

In terms of facilitators, participants explained that treatment access is facilitated when participants have a clear plan, treatment goals, or establish their “why.” A “why” can include reasons spanning from parole requirements to being more present for family members. Finally, correctional staff and patients/family members/caregivers stated that treatment, including treatment via community pharmacies, is facilitated when individual patients are ready to make a change. This can directly relate to a patient’s “why.”

Discussion

Overall, both barriers and facilitators were identified at every level of the Socioecological Model. In general, though, participants identified a higher number of barriers. This aligns with the idea that formerly incarcerated individuals are not utilizing community pharmacist-provided injectable naltrexone upon reentry. In terms of barriers, the most prevalent categories were at the individual level, with the public policy, community, and organizational level having an even mix. The most prevalent barrier categories included lack of interagency collaboration, inability of pharmacists to provide additional OUD services, lack of awareness, lack of insurance, and lack of reliable transportation. A focus on reducing these barriers may be an important and impactful first step in improving access to injectable naltrexone for formerly incarcerated individuals. On the other end of the spectrum, the most prevalent facilitator categories were at the organizational and interpersonal levels. These included the accessible location community pharmacies, flexibility of community pharmacy appointments, and the availability of patient advocates or social support. This not only confirms that community pharmacies are a promising resource, especially due to their accessible locations, but figuring out how to further leverage facilitators, such as patient advocates (peer support specialists, case managers, etc.), can also help improve outcomes.

Overall, there was a high level of concordance between the different stakeholder groups that participated in this study. For example, each of the categories mentioned above were identified by no less than four stakeholder groups, and most were identified by all groups. Additionally, as anticipated, formerly incarcerated individuals and family members/caregivers offered similar perspectives, supporting the decision to include these participants as one stakeholder group. There were only a few examples of discordance noted between the participants. These included discussions of community pharmacy hours and whether or not community pharmacies provide a private and non-judgmental environment for individuals to receive naltrexone injections. Participants from the individual patient/family/caregiver group in particular expressed concerns surrounding privacy and judgement, suggesting that they may have a different perception of the community pharmacy environment compared to other stakeholder groups. With that in mind, providers and support staff should not automatically assume that patients are comfortable receiving MOUD from community pharmacies, and changes to the community pharmacy environment may be necessary to ensure this comfort.

The results also showed a lot of overlap and/or connections between barriers and facilitators. First, while one participant may have identified a specific resource as a facilitator, another may

have noted that the absence of that resource would create a barrier. Second, participants noted that certain factors could have an influence on each other. For example, lack of pharmacy advertising (organizational level) may directly relate to a lack of awareness of community pharmacy services (community level). Similarly, having a social support system (interpersonal level) may help an individual create a plan or identify treatment goals (individual level). Lastly, the high cost of injectable naltrexone (public policy level) may directly limit the availability of community pharmacies that provide this medication (community level).

Many of the barriers and facilitators noted by participants echo what is shown in the existing literature. This is expected, as factors impacting one MOUD option or treatment location are likely to impact access to injectable naltrexone via community pharmacies. For example, lack of insurance or lack of transportation are likely to impact treatment access, regardless of which medication or provider an individual is trying to use.²⁴⁻³⁵ Additionally, previous work has highlighted some of the barriers that community pharmacies face in being able to provide injectable naltrexone services, and many of these factors were identified in this study.²² This is also expected, as barriers to providing certain services are likely to exist regardless of the patient populations or sub-populations who may be using them. However, despite these similar findings, a significant number of categories were also specific to community pharmacist-provided treatment for formerly incarcerated individuals, and most aligned with the organizational and community level. Notably, these categories included 1) lack of interagency collaboration between primary care clinics, correctional facilities, and community pharmacies (exacerbated by patients requiring a prescription prior to injection) and 2) lack of awareness of community pharmacist-provided naltrexone services, especially among correctional staff. Community pharmacists also knew that awareness of their injectable naltrexone services was limited among other professionals and the public. They explained that this was due, in part, to the decision or inability to advertise injectable naltrexone services, which was noted as a barrier at the organizational level.

Limitations

This study presented a few limitations that should be mentioned. First, while the researchers felt that saturation was reached and there was a high level of concordance between the different stakeholders, there were only three to four participants recruited per group. On top of that, certain participants did not have direct experience with coordinating, providing, or receiving community pharmacist-provided injectable naltrexone. These participants discussed anticipated barriers and facilitators based on their perceptions and/or experiences with community pharmacies. Also, this study did not distinguish between formerly incarcerated individuals who were released to the community from jail or prison (either with or without supervision), nor between those who were continuing or initiating injectable naltrexone upon community reentry. Overall, it is possible that saturation was not reached within each stakeholder group, or that the results may have differed with stricter inclusion and exclusion criteria as it relates to the characteristics noted above.

Additionally, several limitations relate to the transferability of the results. The stakeholders included in this study represented several counties across Wisconsin, including urban and rural areas. However, since individuals from every county could not be included, it is possible that the results are not completely representative of all stakeholders' experiences across Wisconsin. The results may also not be generalizable to areas outside of Wisconsin. The smaller sample size also

prevented the researcher from identifying urban and rural differences. Lastly, across all stakeholder groups, the participants were predominantly female, white, and did not identify as Hispanic or Latino, resulting in a homogenous sample. Despite these limitations, this study was intended to be exploratory in nature, and additional work can help ensure the transferability of these results.

Next steps

Future research could focus on confirming these findings by including a larger sample of stakeholders or applying additional triangulation methods, such as utilizing a different framework or methodology. Additionally, as anticipated, the participants did not comprehensively discuss the barriers and facilitators that exist at the public policy level. As a result, next steps should focus on exploring the laws and regulations that impact access to community pharmacist-provided injectable naltrexone for formerly incarcerated individuals in Wisconsin. Next steps should also focus on understanding how the barriers identified in this study can be feasibly addressed through intervention or policy development, especially those that were highly prevalent and/or specific to community pharmacies. Potential interventions could focus on directly reducing barriers or helping formerly incarcerated individuals further leverage resources that support access to community pharmacist-providing injectable naltrexone. Importantly, this work can add to the current research in progress and help emphasize the importance of addressing this healthcare gap. Long-term, these findings may also be scaled-out to areas outside of Wisconsin.

Conclusion

The barriers and facilitators identified in this study provide an opportunity to improve access to community pharmacist-provided injectable naltrexone for formerly incarcerated individuals with OUD. Overall, improving access to these services for this patient population has several social and public health implications, including decreased overdose and rearrest/reincarceration rates. Increased access can also support community health and safety and reduce existing healthcare and legal system costs. This work can also help reduce the racial and ethnic disparities that exist around this problem. Importantly, the results of this study provide a step in improving the community reentry process and ensuring that formerly incarcerated individuals with OUD are not tossed aside, but given the opportunity to receive crucial treatment and successfully reintegrate into society.

References

1. Alexander LM, Keahey D, Dixon K. Opioid use disorder: A public health emergency. *JAAPA*. 2018;31(10):47-52. doi:10.1097/01.JAA.0000545072.09344.ee
2. Azadfard M, Heucker MR, Leaming JM. Opioid Addiction. Florida: StatPearls Publishing. 2023. □ □
3. American Psychiatric Association. Opioid use disorder. <https://www.psychiatry.org/patients-families/opioid-use-disorder>. Accessed May 28, 2024.
4. Wisconsin Department of Health Services. Revised DHS Opioid Settlement Funds Proposal for SFY 2023. <https://www.dhs.wisconsin.gov/publications/p03288.pdf>. Accessed May 28, 2024.
5. Wisconsin Department of Health Services. Dose of reality: Opioids data. <https://www.dhs.wisconsin.gov/opioids/data-reports-studies.htm>. □ Accessed May 28, 2024.
6. Wisconsin Department of Corrections. Opioid overdose deaths and hospitalizations. <https://doc.wi.gov/DataResearch/DataAndReports/OpioidOverdoseReport.pdf>. Accessed May 28, 2024. □ □
7. Substance Abuse and Mental Health Services. Medications for substance use disorders. [samhsa.gov. https://www.samhsa.gov/medications-substance-use-disorders](https://www.samhsa.gov/medications-substance-use-disorders). □ Accessed May 28, 2024.
8. Marsden J, Stillwell G, Jones H, Cooper A, Eastwood B, Farrell M, et al. Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England. *Addiction*. 2017;112(8):1408-1418. □
9. Ranapurwala SI, Shanahan ME, Alexandridis AA, Proescholdbell SK, Naumann RB, Edwards Jr D, et al. Opioid overdose mortality among former North Carolina inmates: 2000–2015. *American journal of public health*. 2018;108(9):1207-1213. □
10. Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O’Grady KE, & Vocci FJ. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. *Drug and alcohol dependence*. 2014;142:33-40. □
11. Magura S, Lee JD, Hershberger J, Joseph H, Marsch L, Shropshire C, & et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. *Drug and alcohol dependence*. 2009;99(1-3):222-230. □
12. Moore KE, Oberleitner L, Smith KM, Maurer K, & McKee SA. Feasibility and effectiveness of continuing methadone maintenance treatment during incarceration compared with forced withdrawal. *Journal of Addiction Medicine*. 2018;12(2):56-162. □
13. Maruschak LM, Minton TD, Zeng Z. U.S. Department of Justice Bureau of Justice Statistics. Opioid Use Disorder Screening and Treatment in Local Jails, 2019. <https://bjs.ojp.gov/library/publications/opioid-use-disorder-screening-and-treatment-local-jails-2019>. Accessed May 28, 2024.
14. Wisconsin Department of Health Services & Wisconsin Department of Corrections. Report on medication-assisted treatment in prisons and jails. <https://www.dhs.wisconsin.gov/publications/p02910-21.pdf>. Accessed May 28, 2024. □
15. Substance Abuse and Mental Health Services. U.S. Department of Health and Human Services. Use of Medication-Assisted Treatment for Opioid Use Disorder in Criminal Justice Settings (Evidence-based Resource Guide Series). <https://store.samhsa.gov/sites/default/files/treatment-criminal-justice-pep19-matusecjs.pdf>. Accessed May 28, 2024.

16. Stahler GJ, Mennis J, Baron DA. Racial/ethnic disparities in the use of medications for opioid use disorder (MOUD) and their effects on residential drug treatment outcomes in the US. *Drug Alcohol Depend.* 2021;226:108849. doi:10.1016/j.drugalcdep.2021.108849
17. Office of the Assistant Secretary for Planning and Evaluation. Health care transitions for individuals returning to the community from a public institution: promising practices identified by the Medicaid reentry stakeholder group. U.S. Department of Health and Human Services.
<https://aspe.hhs.gov/sites/default/files/documents/d48e8a9fdd499029542f0a30aa78bfd1/health-care-reentry-transitions.pdf>. Accessed May 28, 2024.
18. Chladek JS, Chui MA. Access to medications for opioid use disorder for formerly incarcerated individuals during community reentry: a mini narrative review. *Front Public Health.* 2024;12:1377193. Published 2024 May 13. doi:10.3389/fpubh.2024.1377193
19. Krawczyk N, Buresh M, Gordon MS, Blue TR, Fingerhood MI, Agus D. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap. *J Subst Abuse Treat.* 2019;103:1-8. doi:10.1016/j.jsat.2019.05.002
20. Look KA, Dekeyser C, Conjurske S, et al. Illustrating access to community pharmacies in Wisconsin. *J Am Pharm Assoc (2003).* 2021;61(4):492-499. doi:10.1016/j.japh.2021.02.004
21. Berenbrok LA, Tang S, Gabriel N, Guo J, Sharareh N, Patel N, et al. Access to community pharmacies: a nationwide geographic information systems cross-sectional analysis. *J Am Pharm Assoc.* 2022;62:1816–1822.e2. doi: 10.1016/j.japh.2022.07.003 □
22. Ford JH 2nd, Gilson A, Mott DA. Systematic Analysis of the Service Process and the Legislative and Regulatory Environment for a Pharmacist-Provided Naltrexone Injection Service in Wisconsin. *Pharmacy (Basel).* 2019;7(2):59. Published 2019 Jun 12. doi:10.3390/pharmacy7020059
23. Bahji A, Carlone D, Altomare J. Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis. *Addiction.* 2020;115(8):1413-1425. doi:10.1111/add.14946
24. Kaplowitz E, Truong A, Macmadu A, et al. Anticipated Barriers to Sustained Engagement in Treatment With Medications for Opioid Use Disorder After Release From Incarceration. *J Addict Med.* 2023;17(1):54-59. doi:10.1097/ADM.0000000000001029
25. Hall NY, Le L, Majmudar I, Mihalopoulos C. Barriers to accessing opioid substitution treatment for opioid use disorder: A systematic review from the client perspective. *Drug Alcohol Depend.* 2021;221:108651. doi:10.1016/j.drugalcdep.2021.108651
26. Velasquez M, Flannery M, Badolato R, et al. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail. *Addict Sci Clin Pract.* 2019;14(1):37. Published 2019 Oct 1. doi:10.1186/s13722-019-0166-0
27. Fox AD, Maradiaga J, Weiss L, Sanchez J, Starrels JL, Cunningham CO. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder. *Addict Sci Clin Pract.* 2015;10(1):2. Published 2015 Jan 16. doi:10.1186/s13722-014-0023-0
28. Hoffman KA, Thompson E, Gaeta Gazzola M. et al. “Just fighting for my life to stay alive”: a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories. *Addict Sci Clin Pract.* 2023;18(16).
<https://doi.org/10.1186/s13722-023-00377-y>

29. Truong C, Krawczyk N, Dejman M, et al. Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City. *Addict Behav.* 2019;93:14-19. doi:10.1016/j.addbeh.2019.01.020
30. Staton M, Pike E, Tillson M, Lofwall MR. Facilitating factors and barriers for use of medications to treat opioid use disorder (MOUD) among justice-involved individuals in rural Appalachia. *J Community Psychol.* Published online March 17, 2023. doi:10.1002/jcop.23029
31. Martin RA, Gresko SA, Brinkley-Rubinstein L, Stein LAR, Clarke JG. Post-release treatment uptake among participants of the Rhode Island Department of Corrections comprehensive medication assisted treatment program. *Prev Med.* 2019;128:105766. doi:10.1016/j.ypmed.2019.105766
32. Bunting AM, Oser CB, Staton M, Eddens KS, Knudsen H. Clinician identified barriers to treatment for individuals in Appalachia with opioid use disorder following release from prison: a social ecological approach. *Addict Sci Clin Pract.* 2018;13(1):23. Published 2018 Dec 3. doi:10.1186/s13722-018-0124-2
33. Stopka TJ, Rottapel RE, Ferguson WJ, et al. Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers. *Int J Drug Policy.* 2022;110:103803. doi:10.1016/j.drugpo.2022.103803
34. Matsumoto A, Santelices C, Evans EA, et al. Jail-based reentry programming to support continued treatment with medications for opioid use disorder: Qualitative perspectives and experiences among jail staff in Massachusetts. *Int J Drug Policy.* 2022;109:103823. doi:10.1016/j.drugpo.2022.103823
35. King Z, Kramer C, Latkin C, Sufrin C. Access to treatment for pregnant incarcerated people with opioid use disorder: Perspectives from community opioid treatment providers. *J Subst Abuse Treat.* 2021;126:108338. doi:10.1016/j.jsat.2021.108338
36. Lumivero. NVivo (Version 14). www.lumivero.com.
37. Elo S, Kyngäs H. The qualitative content analysis process. *J Adv Nurs.* 2008;62(1):107-115. doi:10.1111/j.1365-2648.2007.04569.x
38. Kilanowski JF PhD Rn Aprn Cnpn Faan. Breadth of the Socio-Ecological Model. *J Agromedicine.* 2017;22(4):295-297. doi:10.1080/1059924X.2017.1358971
39. American College Health Association. Ecological Approach. https://www.acha.org/HealthyCampus/HealthyCampus/Ecological_Model.aspx. Accessed May 28, 2024.
40. Center for Disease Control and Prevention. About Violence Prevention. <https://www.cdc.gov/violence-prevention/about/index.html#:~:text=CDC%20uses%20a%20four%2Dlevel,%2C%20community%2C%20and%20societal%20factors>. Accessed May 28, 2024.
41. Fry JP, Stodden B, Brace AM, Laestadius LI. A Tale of Two Urgent Food System Challenges: Comparative Analysis of Approaches to Reduce High-Meat Diets and Wasted Food as Covered in U.S. Newspapers. *Sustainability.* 2022; 14(19):12083. <https://doi.org/10.3390/su141912083>
42. Akinyemiju T, Ogunsina K, Gupta A, Liu I, Braithwaite D, Hiatt RA. A Socio-Ecological Framework for Cancer Prevention in Low and Middle-Income Countries. *Front Public Health.* 2022;10:884678. Published 2022 May 26. doi:10.3389/fpubh.2022.884678
43. Chen Y, Zhang R, Lou Y, Li W, Yang H. Facilitators and barriers to the delivery of palliative care to patients with Parkinson's disease: a qualitative study of the perceptions and

- experiences of stakeholders using the socio-ecological model. *BMC Health Serv Res.* 2023;23(1):215. Published 2023 Mar 6. doi:10.1186/s12913-023-09203-2
44. Finan SJ & Yap MB. Engaging parents in preventive programs for adolescent mental health: A socio-ecological framework. *Journal of Family Theory & Review.* 2021;13(4):515-527. <https://doi.org/10.1111/jftr.12440>
45. Guzman V, Doyle F, Foley R, et al. Socio-ecological determinants of older people's mental health and well-being during COVID-19: A qualitative analysis within the Irish context. *Front Public Health.* 2023;11:1148758. Published 2023 Mar 23. doi:10.3389/fpubh.2023.1148758
46. Robinson KN, Gresh A, Russell N, Jeffers NK, Alexander KA. Housing instability: Exploring socioecological influences on the health of birthing people. *J Adv Nurs.* 2023;79(11):4255-4267. doi:10.1111/jan.15684
47. Khai TS. Socio-ecological barriers to access COVID-19 vaccination among Burmese irregular migrant workers in Thailand. *J Migr Health.* 2023;8:100194. doi:10.1016/j.jmh.2023.100194
48. Alwan RM, Kaki DA, Hsia RY. Barriers and Facilitators to Accessing Health Services for People Without Documentation Status in an Anti-Immigrant Era: A Socioecological Model. *Health Equity.* 2021;5(1):448-456. Published 2021 Jun 25. doi:10.1089/heq.2020.0138
49. Garney W, Wilson K, Ajayi KV, et al. Social-Ecological Barriers to Access to Healthcare for Adolescents: A Scoping Review. *Int J Environ Res Public Health.* 2021;18(8):4138. Published 2021 Apr 14. doi:10.3390/ijerph18084138
50. Sazzad HMS, McCredie L, Treloar C, Lloyd AR, Lafferty L. Violence and hepatitis C transmission in prison-A modified social ecological model. *PLoS One.* 2020;15(12):e0243106. Published 2020 Dec 1. doi:10.1371/journal.pone.0243106
51. Forero R, Nahidi S, De Costa J, et al. Application of four-dimension criteria to assess rigour of qualitative research in emergency medicine. *BMC Health Serv Res.* 2018;18(1):120. Published 2018 Feb 17. doi:10.1186/s12913-018-2915-2

Glossary/Abbreviations

ADA: American Disabilities Act

AODA: Alcohol and other drug abuse

DOC: Department of Corrections

MOUD: Medications for opioid use disorder

ODU: Opioid use disorder

SAMHSA: Substance Abuse and Mental Health Services Administration

Table 1. Participants by stakeholder group

Role	No. of participants
MOUD prescribers	4
Community pharmacists	3
Correctional staff	4
Community organization or non-profit staff	4
Individual patients OR family members/caregivers	3

Table 2. Categorization matrix for content analysis

	Public Policy	Community	Organizational	Interpersonal	Individual
Barriers					
Facilitators					




Figure 1. The Socioecological Model⁴¹

Table 3. Participant demographics

	MOUD prescribers (n=4)	Community pharmacists (n=3)	Correctional staff (n=4)	Community organization staff (n=4)	Patients, family, caregivers (n=3)	Total (n=18)
Age	40.25	37.33	31.00	39.50	44.67	38.28
Gender						
<i>Male</i>	0 (0%)	3 (100%)	0 (0%)	1 (25%)	1 (33.33%)	5 (27.78%)
<i>Female</i>	4 (100%)	0 (0%)	4 (100%)	3 (75%)	2 (66.67%)	13 (72.22%)
<i>Other</i>	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Ethnicity						
<i>Hispanic/Latino</i>	1 (25%)	0 (0%)	0 (0%)	1 (25%)	0 (0%)	2 (11.11%)
<i>Not Hispanic or Latino</i>	3 (75%)	3 (100%)	4 (100%)	3 (75%)	3 (100%)	16 (88.89%)
Race						
<i>White</i>	4 (100%)	3 (100%)	4 (100%)	4 (100%)	3 (100%)	18 (100%)
<i>Black/African American</i>	0 (0%)	0 (0%)	0 (0%)	1 (25%)	0 (0%)	1 (5.56%)
<i>Asian</i>	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
<i>Native Hawaiian/Pacific Islander</i>	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
<i>American Indian/Alaska Native</i>	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
<i>Other</i>	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Educational Level						
<i>Less than high school</i>	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
<i>High school or equivalent</i>	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (66.67%)	2 (11.11%)
<i>Some college, no degree</i>	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
<i>Associate or Bachelor</i>	0 (0%)	1 (33.33%)	3 (75%)	2 (50%)	1 (33.33%)	7 (38.89%)
<i>Master or above</i>	4 (100%)	2 (66.67%)	1 (25%)	2 (50%)	0 (0%)	9 (50.00%)

Table 4. Categories of barriers and facilitators to community pharmacist-provided naltrexone injections for formerly incarcerated individuals during community reentry

Barriers	Facilitators
<p><i>Public Policy Level</i></p> <ul style="list-style-type: none"> • Cost of drug • Cost of drug testing • Prescription requirement 	<ul style="list-style-type: none"> • OUD classification
<p><i>Community Level</i></p> <ul style="list-style-type: none"> • Stigma • Lack of interagency collaboration • Lack of available prescribers/injectors 	<ul style="list-style-type: none"> • Accessible pharmacy locations
<p><i>Organizational Level</i></p> <ul style="list-style-type: none"> • Administrative constraints • Lack of pharmacy advertising • Inability of pharmacists to provide additional OUD services 	<ul style="list-style-type: none"> • Flexibility of appointments • Non-judgmental environment* • Pharmacy hours*
<p><i>Interpersonal Level</i></p> <ul style="list-style-type: none"> • Negative home/social environment 	<ul style="list-style-type: none"> • Patient advocates/social support • Patient-provider relationship • Treatment reminders
<p><i>Individual Level</i></p> <ul style="list-style-type: none"> • Lack of awareness • Lack of insurance • Lack of reliable transportation • Lack of stable housing • Competing priorities • Medication side effects 	<ul style="list-style-type: none"> • Having a plan and/or goals • Readiness to change

*Categories labeled with an asterisk were discussed as both barriers and facilitators. However, they were placed under the domain they were most commonly identified as.

Table 5. Comparative analysis of barrier categories

	MOUD prescribers (n=4)	Community pharmacists (n=3)	Correctional staff (n=4)	Organization or non-profit staff (n=4)	Patient, family member, or caregiver (n=3)	All stakeholders (n=18)
Cost of drug	1 (25%)	3 (75%)		1 (25%)	1 (33%)	6 (33%)
Cost of drug testing	1 (25%)					1 (6%)
Prescription requirement	1 (25%)	1 (33%)		2 (50%)		4 (22%)
Stigma	1 (25%)		2 (50%)	2 (50%)	1 (33%)	6 (33%)
Lack of interagency collaboration	2 (50%)	3 (75%)	3 (75%)	2 (50%)		10 (56%)
Lack of available prescribers or injectors	3 (75%)		1 (25%)	1 (25%)		5 (28%)
Administrative constraints	2 (50%)	3 (75%)	1 (25%)			6 (33%)
Lack of pharmacy advertising	1 (25%)	2 (67%)				3 (17%)
Inability of pharmacists to provide additional OUD services	3 (75%)	1 (33%)	2 (50%)		1 (33%)	7 (39%)
Negative home or social environment	1 (25%)				1 (33%)	2 (11%)
Lack of awareness	1 (25%)	2 (67%)	1 (25%)	2 (50%)	1 (33%)	7 (39%)
Lack of insurance	3 (75%)	2 (67%)		4 (100%)	2 (67%)	11 (61%)
Lack of reliable transportation	3 (75%)	3 (75%)	4 (100%)	3 (75%)	2 (67%)	15 (83%)
Lack of stable housing	1 (25%)	1 (33%)	1 (25%)	1 (25%)		4 (22%)
Competing priorities	1 (25%)		1 (25%)	1 (25%)		3 (17%)
Medication side effects		1 (33%)	1 (25%)		1 (33%)	3 (17%)

Table 6. Comparative analysis of facilitator categories

	MOUD prescribers (n=4)	Community pharmacists (n=3)	Correctional staff (n=4)	Organization or non-profit staff (n=4)	Patient, family member, or caregiver (n=3)	All stakeholders (n=18)
OD classification				1 (25%)		1 (6%)
Accessible pharmacy locations	3 (75%)	2 (67%)	3 (75%)	1 (25%)	2 (67%)	11 (61%)
Flexibility of appointments	1 (25%)	3 (100%)	1 (25%)	1 (25%)	2 (67%)	8 (44%)
Non-judgmental environment			1 (25%)	2 (50%)		3 (17%)
Pharmacy hours	1 (25%)		1 (25%)		1 (33%)	3 (17%)
Patient advocates and social support	2 (50%)	2 (67%)	2 (50%)	2 (50%)	2 (67%)	10 (56%)
Patient-provider relationship	1 (25%)	1 (33%)	1 (25%)	2 (50%)	1 (33%)	6 (33%)
Treatment reminders		2 (67%)				2 (11%)
Having a plan and/or goals		1 (33%)	1 (25%)	1 (25%)	1 (33%)	4 (22%)
Readiness to change			1 (25%)		3 (100%)	4 (22%)

Table 7. Representative quotes of barrier categories.

Barriers	
Cost of drug	<p>“I mean, the only thing I think that’s frustrating is we’ve tried looking at us giving the injections of [injectable naltrexone], but they’re so expensive.” (MOUD prescriber)</p> <p>“When I’m talking transition, they tend to be a little bit messier, but I think because there’s so much weight on how expensive the [naltrexone] injection is.” (Community pharmacist)</p> <p>“There’s not a very good financial reason to do this service. Like, we’re not getting paid enough money to administer. We’re actually not getting paid any money to administer the drug right now. And, so, I think a lot of community pharmacies are not willing to do the service or invest time in the infrastructure of the services because the return is not...it’s not good.” (Community pharmacist)</p> <p>“That was my initial issue was, like, my insurance wasn’t going to cover it, and I was going to have to pay, like, \$500 out of pocket. Well, I’m, like, newly clean. I don’t have \$500 out of pocket.” (Patient/Family/Caregiver)</p>
Cost of drug testing	<p>“So, there is [a drug test] that actually is out there, and it works. It’s super expensive. And they were going to send us, like, test kits...and they just never sent us test kits.” (MOUD prescriber)</p>
Prescription requirement	<p>“And then, if you don’t have a prescription for it, then that’s one of the biggest barriers. So, I don’t know that, that the systems that they’re leaving always put a prescription in their hands for what they need to continue on.” (Organization staff)</p> <p>“That authorization to actually inject it here through a nice written prescription...And if they forget to click a box within Epic, or if they forget to write us an Rx note that say’s ‘Okay to administer here,’ we’re doing a lot more work of chasing them around...documenting that on the hard copy, printing that out, and making sure that we have it in the patient’s chart.” (Community pharmacist)</p>
Stigma	<p>“Some agent offices, like I said, are super knowledgeable about it, and some don’t want anything to do with that. Because, you know, people are still resistant to some of that stuff.” (Correctional staff)</p> <p>“And then, also, just a lot of stigma in different communities about people taking, like, [injectable naltrexone] or [buprenorphine] or methadone, you know. There’s so much stigma around those medications that some people are just not willing to consider going.” (Correctional staff)</p> <p>“You know, I got some later career physicians who are just, you know, this was not the stuff that they learned in their training. And so, they just don’t have that comfort level with it, and even if they really have no, you know, hands on need to involve themselves in it, I think just the fact, you know, there’s something going on with their patients that they don’t know really what it’s about, it has them a little nervous. And then, I think there are a group of...there’s just kind of this, you know, this farce that, okay, if you open AODA purposes, you’re going to attract a certain flavor of patient to your clinic.” (MOUD prescriber)</p> <p>“I think so many times, people don’t want to go to their primary care doctor because the nurse goes to school with your kids and then, you know, there’s, like, this community stigma associated with it.” (Organizational staff)</p>

<p>Lack of interagency collaboration</p>	<p>“What I keep coming across was the thing that is needed is, like, collaboration. So, that’s where improved outcomes are from. It’s collaboration needs to be improved. And if one person can’t speak with the other, good luck.” (MOUD prescriber)</p> <p>“Like, case managers were trying to connect with people in the jail. That line of communication wasn’t always open. So, that could definitely be improved. And I’d say community providers, in my experience, have been very open and eager and willing to help. But for whatever reason, like, it shouldn’t be rocket science, but for whatever reason there’s that disconnect with the communication in the jail and providers outside of the jail.” (Correctional staff)</p> <p>“And so, with this specific drug, how do we grow our network? How do we go out to know the people in the jails and in the prisons?...So, it seems, you know, it’s very much that the community pharmacists are a great resource. They’re there, and they can play a huge role, but it’s still that collaboration piece. Not just all the things the patients are going through, but actually connecting [correctional organizations] with the community pharmacies.” (Community pharmacist)</p> <p>“I think there’s a lot of assumptions going on that one agency will assume that the other is handling it.” (Community pharmacist)</p> <p>“We always had that hesitation, though. Kind of, like, a stay in your lane kind of thing...Every now and again, you’ll get pushback from somebody who doesn’t really appreciate the whole team-centered approach.” (Community pharmacist)</p> <p>“I mean...releases of information are always a barrier. So, but, yeah, if there aren’t releases of information, and, like, we don’t always get all of the information back...So, maybe the releases of information pieces is a little bit of a barrier, not having the ability to, like, fully communicate one way or the other with that team.” (Organizational staff)</p>
<p>Lack of available prescribers/injectors</p>	<p>“Yeah, I mean, you know, there’s no, there’s no misconception that there is a shortage of healthcare providers in general. So, you know, anything that can be, you know, kind of safely delegated from the clinic to, you know, whoever else...is always a welcome thing” (MOUD prescriber)</p> <p>“It’s always a huge challenge, finding treatment providers or injectors. So, like, for example, if I have a patient that’s releasing, and I don’t know where they’re going, I can always connect them with a telehealth provider, which is great access, but then I have to have somewhere where they can get the injection...And, you know, [clinic] has some contracts with some pharmacies...but it’s not, there’s nothing on a larger scale.” (Organizational staff)</p> <p>“So, before I started working here, they had a doctor that came every Wednesday, and that’s it. So, if you came on a Thursday, you did not see that provider until the following Wednesday...And I can give them the number of the clinic that we use, you know, that they could get medications from, except for, again, that’s usually a big waiting game.” (MOUD prescriber)</p> <p>“So, I don’t think a lot of doctors are getting involved with prescribing or being involved with that patient population other than [county] practitioners who, that’s part of their work.” (Community pharmacist)</p> <p>“We were able to do the injection at [pharmacy]. But an additional barrier is that there wasn’t enough trained staff to be able to administer that.” (MOUD prescriber)</p>

<p>Administrative constraints</p>	<p>“I can go, and I can look at [the electronic health record], right? But that’s all I can do. Pharmacists don’t even have that. Pharmacists actually don’t even have a good charting system for you to document when an injection was given, where it was given, other vital signs, much less track any of that and/or allergies.” (MOUD prescriber)</p> <p>“There is some paperwork involved. And at this point, I don’t have the ability to follow-up with patients. That would probably be something that we would have to institute.” (Community pharmacist)</p> <p>“We do dispense [buprenorphine] and the different forms of films and tablets, but that seems to be less...intense, I guess. Or less, like, I don’t know...there’s less work to be done in that field or that dispensing because naltrexone injections are a lot more time consuming and there’s a lot more questions to be asked before you give someone that.” (Community pharmacist)</p>
<p>Lack of pharmacy advertising</p>	<p>“So, yeah, it’s kind of amazing really that people end up finding their way in there. Because I don’t feel that, like, our system does a very good job of advertising this type of thing.” (MOUD prescriber)</p> <p>“And we’re a small pharmacy, right? We just don’t have the advertising capacity that a larger chain pharmacy might have. But I don’t think we...I don’t think the information on how the injection process goes is widely available. I think that’s something that we ourselves could do a better job on.” (Community pharmacist)</p> <p>“Well, there’s probably a lot of people that don’t even know the service exists. It’s not something that we advertise broadly...So, it’s by word of mouth that my information has gotten out there. But God only knows the other counties, that information might not be shared.” (Community pharmacist)</p>
<p>Inability of pharmacists to provide additional OUD services</p>	<p>“So, my only question with the community pharmacy administering [injectable naltrexone] is that these other places, when our participants would go, they would have at least, like, an hour of counseling what was associated with that. So, it wasn’t just come in, get your treatment, and go...And so, that would be the concern, I guess. Do you lose something if you don’t have that component? Or can the person just be getting that component somewhere else?” (Correctional staff)</p> <p>“There’s this other thing that I think is more important where you should initiate oral meds of naltrexone prior to giving an injection. And that’s from the standpoint, right, like, if you inject someone with [naltrexone], and they happen to be allergic to a component that you weren’t aware of, that’s in their body for 20 days versus a tablet might be there for...I think that’s less restrictive, but still a bit of a barrier.” (Community pharmacist)</p> <p>“[A barrier] can be needing to get, well, so, monitoring labs or doing, just getting, like, bloodwork sometimes. Having access to that.” (MOUD prescriber)</p>
<p>Negative home/social environment</p>	<p>“Because I think that’s every, like, every addict’s main fear, right? Like, am I going to steer clear of, like, these people, these places, these things that are going to bring me down. A lot of people come from families where their mom or dad or sister living the same house as them, and they’re getting high. So, like, am I going to be able to stay away from that?” (Patient/Family/Caregiver)</p> <p>“We did have individuals that would go back to their environment after they were incarcerated and continue using. And, of course, those fold wouldn’t come in for</p>

	<p>their injection, or would come in and test positive.” (MOUD prescriber)</p>
<p>Lack of awareness</p>	<p>“I wasn’t made aware that this was an option until we were trying to sift through, you know, an insurance barrier where the patient had coverage of the medicine if it was given at the pharmacy versus the clinic.” (MOUD prescriber)</p> <p>“So, it’s not...it’s not broad knowledge at all. And I didn’t know that this was an option for years. I only found this out a few years ago, and I’ve been working the field for 15...So, what I think a lot of barriers are, is that people don’t even know this exists. And I think that’s why it doesn’t happen” (Correctional staff)</p> <p>“I don’t think it’s something that people really know is something they can do. Maybe in other areas it’s much more popular. But, like I said, I had no idea.” (Organizational staff)</p> <p>“Just knowing that we provide that service, and they’re unaware of it, could be a barrier also.” (Community pharmacist)</p> <p>“Just a lack of awareness of what’s even out there, available. A lot of people, and again, this is mainly anecdotal based on my interactions with participants, but a lot of them will say, ‘I didn’t even know that there was such as thing of, like, medication-assisted treatment.’ So, not even being aware that there’s something that could help...But then, also, awareness of how to access it. And I think that’s a barrier to people is they just don’t know how to ask for help and where to go.” (Correctional staff)</p>
<p>Lack of insurance</p>	<p>“Another major barrier was this insurance thing where...now this is commercialized insurance, so keep that in mind...but they wouldn’t even cover [injectable naltrexone] on the medical side.” (Community pharmacist)</p> <p>“In addition to that, I think insurance is a huge, you know, huge barrier. We have been able to now with the Medicaid changes in our state, we have jail reentry coordinator...at least be able to sign folks up before they leave...but I still think people are being missed.” (Organizational staff)</p> <p>“I would say, you know, insurance is a huge barrier for this population. So, I’d say, just their ability to return for a follow-up is sometimes very limited, and then whatever coverage they might have for their medical care could be limited.” (MOUD prescriber)</p> <p>“Yeah, so, the biggest barrier for anybody with anything after they’re released is having insurance. Because when someone is incarcerated, it’s turned off...And so, the funding of any treatment after release is always a huge challenge.” (Organizational staff)</p>
<p>Lack of reliable transportation</p>	<p>“They don’t have transportation. And [company], which is the state transportation of folks on Medicaid or Medicare, it’s an awful system. It’s not...they don’t show up a lot.” (Organizational staff)</p> <p>“So, I mean, I think, you know, a lot of people have transportation barriers... You know, a lot of my patients have revoked driver’s license right now. So, you know, their transportation is very limited.” (MOUD prescriber)</p> <p>“Transportation is always a problem I would say. Unless somebody has a very solid system in the community, they tend to struggle.” (Correctional staff)</p>

	<p>“So, like, I definitely think, like, more reliable transportation...Like, you need reliable transportation, especially for things, like, that are, like, life threatening. Which his the same for [injectable naltrexone], you know? Like, if you can’t get there and get the injection, and it’s not even your fault, like, then what?” (Patient/Family/Caregiver)</p>
Lack of stable housing	<p>“You know, the hard part is, you know, when I see these people, they’re commonly in an unstable living condition situation. They’re kind of couch surfing. They don’t know where they’re going to be from day to day. I’ve got one client who is, you know, residing at the YMCA and, you know, it’s touch and go.” (MOUD prescriber)</p> <p>“I notice a lot fail or are inconsistent with treatment...whether it’s [injectable naltrexone] or just, you know, AODA group or classes...they really struggle to be consistent with that if they don’t have housing...They’re constantly in fear that they don’t have a secure place.” (Correctional staff)</p> <p>“A lot of times, you’re relying on those patients to be adherent, and they don’t have, you know, places to even keep things. They have a backpack on them, and that’s it.” (Community pharmacist)</p> <p>“I think, you know, housing stability, like, in their, you know, outside life...Like if they don’t have stable housing, they don’t show up a lot.” (Organizational staff)</p>
Competing priorities	<p>“Another barrier that we found for our clinic was we have these individuals that we are trying to get them re-established in the community in a healthy way. They have a job and want to be involved with their children and so on and so forth. So, to be able to take time off of work when they just started this job during normal business hours...some of them are like ‘I understand I need this shot, but I also need this job.’” (MOUD prescriber)</p> <p>“So, the priority is on trying to get a job. It’s on trying to get a safe place to sleep. It’s trying to figure out how do I make it to my parole agent’s office that is ten miles from where I am. So, those are very legitimate challenges that these men and women are facing. And I think that makes it even more difficult for them to pursue treatment.” (Correctional staff)</p>
Medication side effects	<p>“A flu shot is half an mL of aqueous solution, right? So, it goes in the body really fast, and it’s not very much. [Injectable naltrexone] is 4.2 mLs, basically creates a small depot, right? And it’s slowly dispersed in the body. So, a lot of people will experience pain and don’t have a high pain tolerance. Then it doesn’t really work for them.” (Community pharmacist)</p> <p>“That sometimes really scares them and turns them away, I’ve noticed. Like, I’ve had a couple guys be like, ‘I was really interested, but then I read all those side effects.’” (Correctional staff)</p> <p>“It’s one of the worst shots you can get. You are sore for, like, two weeks after getting that thing.” (Patient/Family/Caregiver)</p>

Table 8. Representative quotes of facilitator categories

Facilitators	
<p>OUO classification</p>	<p>“The ADA actually made opioid use disorder a disability, which gives them protected</p>

	rights to continue the treatment as well.” (Organizational staff)
<p>Accessible pharmacy locations</p>	<p>“It’s more accessible for certain people who may not have cars or a bus route that leads to the doctor. It’s just more accessible.” (Patient/Family/Caregiver)</p> <p>“But if they’re comfortable doing that, then you have, you know, a pharmacy close by that they can walk to to have that done...One of the things we hear, sort of, in thinking about community pharmacies, one of the things you always hear is, like, the accessibility because there are locations everywhere.” (MOUD prescriber)</p> <p>“And so, if there was, you know, if there was an issue getting, you know, to one place or the other, you know, there’s a community pharmacy, you know, in walking distance to them that they wouldn’t have to get on a the bus or get a ride or all that kind of thing.” (MOUD prescriber)</p> <p>“If people could wake up and go down the road to [pharmacy] and get the shot, that would be huge.” (Patient/Family/Caregiver)</p> <p>“There’s so many pharmacies all over the place, so they could just walk to you and get it. They don’t have to stress about, okay, got to have enough money for a bus ticket or, like, got to make sure I have a family member lined up to drive me.” (Correctional staff)</p>
<p>Flexibility of appointments</p>	<p>“I have the ability of getting people in and out of here with a very short notice. It’s not like needing an appointment a month in advance, or three days in advance. It’s typically, hey, they’ve had their drug screening, or I’m going to bring them in next week, what time works best?” (Community pharmacist)</p> <p>“But I think it’s reasonable to get back in within 24 hours or missing your appointment. Because if you think about it from a clinic or hospital side, if you miss your appointment, like, you’re probably not back in for at least a month.” (Community pharmacist)</p> <p>“I think that would be very beneficial. And if you’re not comfortable at a pharmacy, it’s so easy to switch to a different pharmacy. A lot easier than going to a different treatment center.” (Correctional staff)</p>
<p>Non-judgmental environment</p>	<p>“Where I guess the pharmacy, to me anyway, doesn’t seem like it would carry the same...because they know everybody’s secrets. They know everything, everybody’s treatment. But yet, you don’t really worry about the pharmacist telling somebody you just bought a fungal cream or whatever...If a pharmacist had a desire to treat these folks, it could also be a very nonjudgemental environment for people to receive care.” (Organizational staff)</p> <p>“I think that community pharmacists are more likely, or less likely I should say, to be judgmental than maybe your [clinics].” (Organizational staff)</p> <p>“A lot more clients, I feel like, if they got set up, and they’re, like, prescribed, would rather go to a pharmacy and go get a shot where it doesn’t really look like you’re going to these specified treatment facilities where everyone in there knows that you have a substance use disorder. You can go into your neighborhood pharmacy, where you’ve been known for years. Like, you know, everyone in there gets a shot. You can play if off as whatever you want to play it off as.” (Correctional staff)</p>
<p>Pharmacy hours</p>	<p>“Because it can work around more, like, hey, I’m leaving for work at this time. Let me just go get my shot before I go to work. I feel like it will help their schedule a lot</p>

	<p>too.” (Correctional staff)</p> <p>“Pharmacies are open on the weekends and later in the evenings. I know some pharmacies that are open at 7 a.m. So, I feel like that accessibility of time.” (MOUD prescriber)</p> <p>“I feel like [community pharmacies] are more flexible with their hours.” (Patient/Family/Caregiver)</p>
<p>Patient advocates/social support</p>	<p>“There are certainly case managers...I guess that’s a broad label...but they will work with patients who can set up appointments for themselves or figure out how to get rides, transportation for patients. And that seems to be more successful.” (Community pharmacist)</p> <p>“In many ways, family members are amazing. Like, ‘My brother is going to pick me up and take me to the clinic.’ And also having [peer support specialists] has really helped it flow and taken the pressure off a lot of people.” (Organizational staff)</p> <p>“Just, like, having a new support system...And so, I think making sure they find someone who’s a peer support or someone that maybe is a new support that wasn’t in their life. So, a few of my guys come out and they have, like, a priest, friends, or pastors...I think having someone that keeps them accountable is very helpful.” (Correctional staff)</p> <p>“Most folks, if they’re serving, like, a jail sentence, they get out at 4 a.m. Nothing good happens at 4 a.m. And even if you did have a, you know, prescriber of treatment or appointment at 6 a.m., you still have two hours...you know, a lot can happen in two hours depending on who picks you up from jail. And we have peer providers that will do that a lot of times and, like, hang out with them, take them to breakfast, and then take them to their appointment, so that they’re not, you know, jumping in the car with somebody else that, you know, they used to hang out with before, and they’re, like, off to the races, and they don’t...you know...like, that appointment is no longer a priority for them.” (Organizational staff)</p>
<p>Patient-provider relationship</p>	<p>“I think it goes back to being invested in their, in their well-being...I’m biased, but I think we do a better job than some of our competitors...We take, we take the extra time, and we are trying to re-envision some of our models as patient-centered...For some, it’s a name on the screen. It’s another prescription. Taking that mentality and flipping it and trying to think of, you know, if this were my loved one...This is not just a name on the screen. These are my patients that are, you know, keeping the lights on. So, we’ve been trying to change that mentality, and it’s been going really, really well.” (Community pharmacist)</p> <p>“You have to find a way to motivate them and help them understand that you are here for them, while giving them the inspiration and motivation to let them know that you can do this.” (Organizational staff)</p> <p>“So, a lot of the important part of is just, you know, explaining to them, you know, your role in this. Like, I’m here to make this happen for you, and you know this is what I want to do for you, and getting their trust and getting their buy-in, and, you know, kind of helping them to know that, you know, I’m not just part of their punishment. I’m hopefully trying to be, you know, part of their recovery.” (MOUD prescriber)</p> <p>“People who are recently released, respect is a big thing. So, as soon as they don’t feel respected, they’re really going to shut down, and they’re ready to be just, like,</p>

	<p>yeah, no, I'm done." (Correctional staff)</p>
<p>Treatment reminders</p>	<p>"We have a newer system now that does text and phone call reminders. We started off with just making physical, manual phone calls, you know, person to person, making sure you're talking to somebody. And now we have the ability to send off text messages to say, 'Hey, your appointment is coming up.'" (Community pharmacist)</p> <p>"We do offer text messages when the prescription is filled. So, that could be a reminder that they need to show up for their appointment...But I know that they're coming in the next day, so I will queue up the [injectable naltrexone] prescription to be filled that next day. So, they'll get a text as soon as that's done." (Community pharmacist)</p>
<p>Having a plan and/or goals</p>	<p>"I talk to patients the first time I meet with them about establishing their "why" of why you are here... whether it's court-ordered or whether you're here because you want to better yourself. [Injectable naltrexone] in itself is not something that is going to be a quick fix. It's not something that you're going to get your injection and today I'm never going to use again. Whether it's alcohol or opioid, you need to have some sort of mentality and, sort of, drive as to why you want to get healthy." (Community pharmacist)</p> <p>"There's also, like, a goal setting worksheet. So, like, their short-term, long-term goals, how, like, they should involve their support with [injectable naltrexone], how they can better manage with counseling...so, that's been [a facilitator]" (Correctional staff)</p>
<p>Readiness to change</p>	<p>"There was a more serious effort with [his] side. You know, wanting to improve his life and get out of the lifestyle... You saw the difference and the attitude change." (Patient/Family/Caregiver)</p> <p>"Fortunately, at that time, I was ready to make a change. And that was a big thing too." (Patient/Family/Caregiver)</p> <p>"And so, going into it the second time, being more ready, being more willing. It was a game changer for me." (Patient/Family/Caregiver)</p> <p>"I think a lot boils down to somebody's, like, readiness to change, right? Like people actually buying in, wanting to engage right out of custody." (Correctional staff)</p>